originally published at Health - Purple Foxy Ladies
Through involvement in the clinical trial process, doctors at Mid Atlantic Retina played a key role in obtaining FDA approval for pegcetacoplan.
Through involvement in the clinical trial process, doctors at Mid Atlantic Retina played a key role in obtaining FDA approval for pegcetacoplan.
PHILADELPHIA, April 21, 2023 (Newswire.com) - Physicians at Mid Atlantic Retina are proud to announce the approval of pegcetacoplan by the U.S. Food and Drug Administration (FDA), a groundbreaking new treatment for dry age-related macular degeneration (dry AMD) with geographic atrophy (GA). FDA approval of intravitreal pegcetacoplan came after three phases of clinical trials conducted over a 24-month period, with direct involvement by Mid Atlantic Retina (and Wills Eye Hospital) physicians during the phase 2 and crucial stage 3 clinical trial periods.
As a Center for Excellence in treating retinal diseases, Mid Atlantic Retina provides patients with the latest in cutting-edge treatments and techniques for various retinal conditions. This includes involvement in clinical research programs investigating advances in surgical techniques, procedures, and pharmaceuticals.
With clinical study support leading up to the historic approval of pegcetacoplan, the specialists at Mid Atlantic Retina - part of the larger Will Eye Hospital team - continue demonstrating their commitment to ensuring individuals have access to the most advanced, effective treatments available.
"FDA approval of our first-ever therapy to slow the progression of geographic atrophy allows us to help patients who otherwise often have a relentlessly progressive form of AMD that can be visually debilitating as time goes on," - lead investigators Allen Chiang, MD, Mitchell S. Fineman, MD, and Sunir J. Garg, MD, FACS, FASRS.
The physicians at Mid Atlantic Retina played an integral part in developing this drug over a five-year period when it was tested on a broad range of patients with GA. Through engagement in the clinical study process, the Mid Atlantic Retina team helped prove the efficacy, safety, and tolerability of pegcetacoplan - an effort that ultimately led to FDA approval.
The progression of macular degeneration into GA and late-stage retinal atrophy can lead to partial or full vision loss without adequate treatment. Pegcetacoplan has been shown to slow or stop the progression of GA, preserving vision for individuals with progressive dry AMD. To learn more about pegcetacoplan as well as the many clinical study programs available, contact Mid Atlantic Retina and schedule a consultation with an expert retina specialist.
About Mid Atlantic Retina
Mid Atlantic Retina is a top retina practice with experienced board-certified physicians and surgeons from world-renowned Wills Eye Hospital. For over 50 years, Mid Atlantic Retina physicians have provided patients with top-rated care for a wide range of retinal conditions. Mid Atlantic Retina remains one of the premier retina practices, with the largest training program in the United States and over 1,000 published research papers in the past ten years alone. Their team is highly involved in leadership roles and speaking engagements on retinal care nationally and internationally. The practice operates in multiple locations in Pennsylvania, New Jersey, and Delaware.
For more information, visit www.midatlanticretina.com.
Contact Information:Mid Atlantic Retina
(800) 331-6634
Original Source: Mid Atlantic Retina Physicians Part of Clinical Trial Team for Groundbreaking New Macular Degeneration Medication
